Ajooni Biotech Limited has informed the Exchange regarding 'Ajooni Biotech Reports Strong Q4 FY25 Result With Growth Of 68.29% In PAT On YoY Basis'.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech Limited, a pure veg animal health care and cattle feed company, reported audited financials for Q4 FY25 and FY25. Total income for Q4 FY25 stood at ₹30.61 crore, up 54.28% year-on-year, while full-year FY25 total income was ₹116.76 crore, up 41.85%. Profit after tax (PAT) grew 68.29% YoY to ₹1.54 crore in Q4 and 56.02% to ₹3.37 crore for the full year. EBITDA margins for Q4 stood at 7.68% and FY25 at 4.93%, with EBITDA growing 27% and 30% respectively. The company also highlighted operational milestones including BIS certification, ZED GOLD certification, entry into B2C, expansion to 300+ dealers, a new MOU for North India operations, and repeat export orders.
Strong double-digit growth in both revenue and profit, combined with margin expansion in Q4, signals improving business momentum and may be viewed positively by investors. The new certifications, dealer network expansion, and B2C entry suggest the company is building a foundation for sustained future growth.